Advent Life Sciences — Full Portfolio

Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.

BiotechHealthtechMedical DevicesCambridge, US

Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos, Ph.d.(President and Treasurer)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)

Co-investorsChiesi VenturesDroia VenturesForesite CapitalJazzya InvestmentsMedicxiMyelin VC+4 more

Emergent BioSolutions is a public health company that develops, manufactures, and supplies medical countermeasures for national security and preparedness, along with commercialized products addressing threats such as the opioid epidemic.

Advanced ManufacturingBiotechHealthtechGaithersburg, US

Fuad El-Hibri(Director, Executive Officer)Robert G Kramer(Executive Officer)Katherine Strei(Executive Officer)Adam R Havey(Executive Officer)Daniel J Abdun-Nabi(Executive Officer, Director)Zsolt Harsanyi(Director)

Co-investorsOrbiMed

Shionogi is a pharmaceutical company that discovers and develops medicines for challenging human diseases, including antibiotics and treatments for HIV, influenza, and COVID-19.

BiotechHealthtech

Co-investorsSolas BioVentures

Relief Cardiovascular develops transcatheter smart implant systems for volume management in congestive heart failure, including the Relief System, a preload-modulating implant for inferior vena cava flow modulation with autonomous hemodynamic monitoring.

BiotechHealthtechMedical DevicesCosta Mesa, US

Co-investorsBroadview VenturesGood Growth Capital

Tridek-One Therapeutics develops bispecific antibodies that agonize the CD31 ITIM inhibitory checkpoint receptor to modulate immune cell activation for inflammatory and autoimmune diseases.

BiotechDeep TechHealthtechParis, FR

Co-investorsBioqube VenturesBpifrancePureos BioventuresAdBio partners

Arrakis Therapeutics develops RNA-targeted small-molecule (rSM) medicines, working independently and with partners to create drug candidates aimed at the root causes of disease.

AI & Machine LearningBiotechDeep TechHealthtechCambridge, US

Michael Gilman(Executive Officer, Director)Mark DeLong(CEO)David Neafus(Executive Officer)Russell C. Petter(Executive Officer)

BoardColleen Cuffaro(Director)inAlan E. Walts(Director)in

Board seatRaj ParekhAlan Walts· per SEC Form D

Co-investorsCanaan PartnersPfizer VenturesNextech InvestOUP (Osage University Partners)Pfizer Venture InvestmentsvenBio Partners+1 more

Artax Biopharma is a Phase 2 clinical-stage biotechnology company developing first-in-class oral small-molecule Nck modulators that target T cell receptor Signal 1 activation to treat autoimmune diseases without causing immunosuppression.

BiotechHealthtechCambridge, US

Damia Tormo(President, CEO, Treasurer and Founder)Joe Suarez(Executive Officer)Maria Nichol(Executive Officer)Robert W. Armstrong, Ph.D.(Executive Officer, Director)Rob Armstrong(CEO)Jan de Vries, Ph.D.(Director)

Board seatRaj ParekhAlan Walts· per SEC Form D · $19M raise · filed May 2026

Co-investorsSound BioventuresColumbus Venture Partners

Uses a T-cell antigen discovery platform to develop vaccines for oncology and infectious disease.

BiotechCambridge, US

Narinder Singh(Executive Officer)Derek Meisner(Executive Officer)Michael Alfieri(Executive Officer)Jessica Flechtner(Executive Officer)Girish Aakalu(Executive Officer)Thomas Davis(Executive Officer)

Board seatKatrine Bosley· per SEC Form D · $15M raise · filed Feb 2019

Co-investorsCycad Group LLCLux CapitalMC Healthcare VenturesNew Enterprise Associates (NEA)

BiotechWatertown, US

Edward Mascioli(Executive Officer)Andrew Myers(Director)

BoardMarkus Goebel(Director)Henry Skinner(Director)Vikas Goyal(Director)

Board seatRaj Parekh· per SEC Form D · $20M raise · filed Mar 2018

Co-investorsRoche Venture Fund

HealthtechFremont, US

Anton Clifford(Executive Officer)James Leech(Executive Officer)Christopher Gleason(Executive Officer)Kevin K. Sidow(Executive Officer, Director)

BoardJoshua Makower(Director)

Board seatShahzad Malik· per SEC Form D

Co-investorsLightstone VenturesNew Enterprise Associates (NEA)Runway Growth CapitalGBS Venture Partners Ltd.Gilde HealthcareVertex Ventures HC

HealthtechCarlsbad, US

Christoph Scharf(Director)inRandy Werneth(Executive Officer, Director)Graydon Beatty(Executive Officer)inVince Burgess(Director)John Dahldorf(Executive Officer)

BoardAditya Puri(Director)

Co-investorsOrbiMedDeerfield Management CompanyGE VenturesIndex Ventures

Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.

BiotechCambridge, GB

Louise Modis(Chief Executive Officer)Martin Pass(Chief Development Officer)Giles Brown(Executive VP Drug Discovery)

Co-investorsNovartis Venture FundSV Health InvestorsDementia Discovery FundEuropean Investment FundForbionGilde Healthcare+1 more

BiotechHouston, US

Amato Giaccia(Director)Rudy Howard(Chief Financial Officer)Robert B. Geller(Chief Medical Officer)Gail McIntyre(Chief Executive Officer)Leonard Scott Dove(Chief Operating Officer)Joshua Brumm(Executive Officer)

Co-investors3E Bioventures Capital

AviadoBio is a biotech company developing gene therapies for neurodegenerative diseases, starting with frontotemporal dementia.

BiotechHealthtechMedical Devices

AviadoBio is a gene therapy company developing adeno-associated viral (AAV) treatments for neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

BiotechDeep TechDigital HealthHealthtech

Chris Shaw(Co-Founder & Chief Scientific and Clinical Advisor)Do Young Lee(Co-Founder)Youn Bok Lee(Co-Founder)Lisa Deschamps(Chief Executive Officer)Graeme Fielder(Chief Operating Officer)Alex Bloom(Chief Development Officer)

Co-investorsDementia DiscoveryF-Prime CapitalLifeArc VenturesMonograph Capital PartnersNew Enterprise Associates (NEA)

Boston Scientific develops medical devices and technologies used by healthcare professionals to treat patients across a range of conditions.

HealthtechMedical Devices

Raymond Cohenin

Co-investorsAndera PartnersLongitude Capital

Co-investorsOxford Science Enterprises

Biocartis develops Idylla, a fully automated real-time PCR molecular testing system that delivers biomarker results in about three hours for oncology applications.

BiotechHealthtechMedical Devices

Co-investorsKorysNew Rhein Healthcare Investors, LLCPMV

Co-investors415 Capital

The Centers for Disease Control and Prevention (CDC) is a US federal public health agency that provides health information, disease outbreak alerts, vaccination guidance, and scientific data to the public.

Digital HealthGovTech

Co-investorsAndera Partners

Centessa is a biopharmaceutical company developing an Orexin Receptor 2 Agonist program aimed at treating sleep-wake, neurological, neurodegenerative, and neuropsychiatric disorders.

BiotechHealthtech

Co-investorsEcoR1 CapitalForesite CapitalMedicxiOberland CapitalScion Life SciencesVida Ventures+1 more

Epitopea develops off-the-shelf cancer vaccines targeting aberrantly expressed tumor-specific antigens using its proprietary CryptoMap platform.

AI & Machine LearningBiotechHealthtechMontreal, CA

Claude PerreaultPierre Thibault

Co-investorsCambridge Innovation CapitalCTI Life Sciences Fund L.P.adMare BioInnovationsFonds de solidarité FTQ

Co-investorsEssex Woodlands Healthcare PartnersSV Health Investors

F2G is a biotechnology company developing novel antifungal therapies to treat rare, life-threatening fungal infections in defined patient populations.

BiotechHealthtech

Co-investorsAisling CapitalAMR Action FundAstellas Venture Management LLCBrace PharmaSofinnova PartnersSunstone Capital+3 more

Co-investorsAvedro, Inc.

Developing therapies for congenital disorders of glycosylation combining replacement therapies with intracellular delivery vehicles.

BiotechSan Francisco, US

Christopher Starr(Director)Peter C.M. McWilliams(Director)Agnes Rafalko(Executive Officer, Director)

BoardGiacomo Chiesi(Director)

Co-investorsChiesi VenturesCTI Life Sciences Fund L.P.Remiges Ventures, Inc.RiverVest Venture PartnersSanderling VenturesSanofi Ventures

Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.

Biotech

Steven Axon(Chief Executive Officer)Hicham Alaoui(Chief Scientific Officer)Rose Marino(Chief Medical Officer)Peter McWilliams(Chief Business Officer)Geoffrey Hird(Chief Technology Officer)

Co-investorsMission Bay CapitalMission BiocapitalRemiges Ventures, Inc.RiverVest Venture PartnersSanderling VenturesSanofi Ventures

Co-investorsAisling CapitalNew Enterprise Associates (NEA)Prospect Venture Partners

Little Dog Communications is a public relations and corporate communications firm serving biotech and life science companies, offering press releases, media outreach, websites, and investor presentations.

BiotechMarketing TechSan Diego, US

Jessica Yingling(President)

A therapeutics company developing checkpoint agonist antibodies for autoimmune disease treatment based on Oxford University research (exited August 2022).

Co-investorsMedicxiMonograph Capital PartnersOxford Science EnterprisesSamsara BioCapital

Nalu Medical develops a non-integrated neurostimulation system that uses electrical impulses to interrupt pain signals for patients with intractable chronic nerve pain.

HardwareHealthtechMedical DevicesCarlsbad, US

Earl Fender(President & CEO)Lee Hartley(Executive Officer)Allen Meacham(Executive Officer)Bick Sellers(Executive Officer)Thomas A. West(Executive Officer, Director)Jeffrey Swiecki(Executive Officer)

Co-investorsAPERTURE Venture PartnersB Capital GroupB4 CapitalDecheng CapitalEndeavour VisionLongitude Capital+1 more

ClinicalTrials.gov is a public registry and results database of clinical studies conducted around the world, maintained by the U.S.

Digital HealthHealthtech

Co-investorsYsios Capital

Co-investorsFountain Healthcare PartnersOrbiMedColumbus Venture Partners

Orphalan is a global pharmaceutical company that identifies, develops, and commercializes orphan drugs for patients with rare diseases, including treatments for Wilson disease.

BiotechHealthtech

Developing PTD802, a therapeutic candidate for multiple sclerosis (received FDA IND clearance).

Co-investorsLifeArc Ventures

Pheno Therapeutics is a clinical-stage biotech company developing GPR17 antagonists that target oligodendrocytes to promote brain repair.

BiotechMedical DevicesEdinburgh, GB

Neil Carragher(Founder)

Co-investorsLifeArc Ventures

BiotechBoston, US

Dr. Richard Peters(Director)Belinda Termeer(Director)Dr. Alan E. Walts(Director)inDr. Gerhard Wagner(Director)Sun Altbach(Executive Officer, Director)

Co-investorsLumira VenturesOrbiMed

Proximie provides a cloud-based operating system for connected operating rooms, giving medtech companies and hospitals real-time OR connectivity, structured surgical data, and AI-driven insights.

AI & Machine LearningDigital HealthMedical DevicesSaaSAltrincham

Nadine Haram(Director)Nadine Hachach-Haram(Founder)Jonathan Lim(Director)inScott Huennekens(Director)

BoardMohammed Shahzad Ahmed Malik(Director)

Co-investorsCapria VenturesCedar Mundi VenturesCOTU VenturesDraper AssociatesF-Prime CapitalQuesta Capital+2 more

Rappta Therapeutics develops a first-in-class series of anti-cancer molecular glues that reactivate the tumor suppressor enzyme PP2A (protein phosphatase 2A).

BiotechHealthtech

Co-investorsNovartis Venture FundNovo Holdings

Co-investorsF-Prime Capital

Develops first-in-class CD31-ITAM immune modulating bispecific antibodies for auto-immune and inflammatory disorders.

Co-investorsAdBio partners

uniQure is a gene therapy company developing treatments for Huntington's disease and other serious medical conditions.

BiotechHealthtech

Matthew Kapustain

Co-investorsForesite CapitalHEALTHCARE ROYALTY PARTNERS

Zyme Communications is a specialist agency offering PR, marketing, design, branding, and investor relations services to companies in the life science sector.

BiotechMarketing Tech